Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Nat Struct Mol Biol. 2010 Feb;17(2):151-8. doi: 10.1038/nsmb.1743. Epub 2010 Jan 10.
Gamma-secretase is an aspartyl protease that cleaves multiple substrates within their transmembrane domains. Gamma-secretase processes the amyloid precursor protein (APP) to generate gamma-amyloid (Agamma) peptides associated with Alzheimer's disease. Here, we show that APP possesses a substrate inhibitory domain (ASID) that negatively modulates gamma-secretase activity for Agamma production by binding to an allosteric site within the gamma-secretase complex. Alteration of this ASID by deletion or mutation, as is seen with the Flemish mutation (A21G), reduces its inhibitory potency and promotes Agamma production. Notably, peptides derived from ASID show selective inhibition of gamma-secretase activity for Agamma production over Notch1 processing. Therefore, this mode of regulation represents an unprecedented mechanism for modulating gamma-secretase, providing insight into the molecular basis of Alzheimer's disease pathogenesis and a potential strategy for the development of therapeutics.
γ-分泌酶是一种天冬氨酸蛋白酶,可在跨膜结构域内切割多种底物。γ-分泌酶将淀粉样前体蛋白(APP)加工为与阿尔茨海默病相关的γ-淀粉样肽(Agamma)。在这里,我们表明 APP 具有底物抑制结构域(ASID),该结构域通过与 γ-分泌酶复合物内的变构位点结合,负调控 Agamma 的产生。通过缺失或突变(如 Flemish 突变(A21G))改变该 ASID,会降低其抑制效力并促进 Agamma 的产生。值得注意的是,来自 ASID 的肽显示出对 Agamma 产生的 γ-分泌酶活性的选择性抑制作用,而对 Notch1 加工的抑制作用较小。因此,这种调节模式代表了调节 γ-分泌酶的一种前所未有的机制,为阿尔茨海默病发病机制的分子基础提供了深入了解,并为治疗药物的开发提供了一种潜在策略。